METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY

The present invention relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HONG, Jung-Hyub, KANG, Myeongho, JEONG, Yideul, BAE, Yong-Soo
Format:	Patent
Sprache:	eng ; fre ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	HONG, Jung-Hyub KANG, Myeongho JEONG, Yideul BAE, Yong-Soo
description	The present invention relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a pharmaceutical composition and kit comprising same for cancer immunotherapy, the method comprising a step of treating dendrocyte progenitor cells with interleukin-33 (IL-33) when the dendrocyte progenitor cells are cultured in a medium containing FMS-like tyrosine kinase 3 ligand (Flt3L) and thus differentiated to dendritic cells. As the dendritic cells differentiated by the preparation method of the present invention exhibit a high potential of inducing antigen-specific cytotoxic T cells, compared to control dendritic cells, and antitumor immunity is strongly induced by a subpopulation of the newly differentiated dendritic cells, the preparation method of the present invention has the advantage of increasing immunogenicity in the differentiation step in contrast to a convention method of increasing immunogenicity after completion of differentiation to dendritic cells. Therefore, it is expected that novel immune cell therapy capable of greatly increasing a therapeutic effect through the preparation method of the present invention and dendritic cells cultured ex vivo using same can be provided. La présente invention concerne un procédé d'augmentation de l'immunité antitumorale d'un agent thérapeutique dendrocytaire et, plus spécifiquement, un procédé de préparation de cellules dendritiques positives à la classe de différenciation 103 (CD103), des cellules dendritiques positives à CD103 préparées par le procédé de préparation, ainsi qu'une composition pharmaceutique et un kit les comprenant pour une immunothérapie anticancéreuse ; le procédé comprenant une étape de traitement de cellules progénitrices dendrocytaires avec l'interleukine-33 (IL-33) lorsque les cellules progénitrices dendrocytaires sont cultivées dans un milieu contenant un ligand de tyrosine kinase 3 de type FMS (Flt3L) et ainsi différenciées en cellules dendritiques. Étant donné que les cellules dendritiques différenciées par le procédé de préparation de la présente invention présentent un potentiel élevé d'induction de lymphocytes T cytotoxiques spécifiques d'un antigène, par rapport aux cellules dendritiques témoins, et que l'immunité antitumorale est fortement induite par une sous-population des
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022108306A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022108306A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022108306A13</originalsourceid><addsrcrecordid>eNqNjr9KxEAQxtNYyOk7DFhKIMmC2I67k-xidnaZTDhSHcexVqIH5wv6ZiZylZXV9xXfn99t9R1JfXLQJ4EslFECDxBinDkNxMEGXWpij2zJgXVtYx6ht4Os4oidBA0WLI0jvCygQqiRWGEf1ENgJRlpfg1cGwPIDrJHiWhpXms4gk0xp2ndSPzrJUzb_4SR_s5vhHbDkCueehLMy11183Z8v5T7q-6qh57U-rqcPw_lcj6eykf5OuxT13Rd2zyb5glb87_UD71oTnY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY</title><source>esp@cenet</source><creator>HONG, Jung-Hyub ; KANG, Myeongho ; JEONG, Yideul ; BAE, Yong-Soo</creator><creatorcontrib>HONG, Jung-Hyub ; KANG, Myeongho ; JEONG, Yideul ; BAE, Yong-Soo</creatorcontrib><description>The present invention relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a pharmaceutical composition and kit comprising same for cancer immunotherapy, the method comprising a step of treating dendrocyte progenitor cells with interleukin-33 (IL-33) when the dendrocyte progenitor cells are cultured in a medium containing FMS-like tyrosine kinase 3 ligand (Flt3L) and thus differentiated to dendritic cells. As the dendritic cells differentiated by the preparation method of the present invention exhibit a high potential of inducing antigen-specific cytotoxic T cells, compared to control dendritic cells, and antitumor immunity is strongly induced by a subpopulation of the newly differentiated dendritic cells, the preparation method of the present invention has the advantage of increasing immunogenicity in the differentiation step in contrast to a convention method of increasing immunogenicity after completion of differentiation to dendritic cells. Therefore, it is expected that novel immune cell therapy capable of greatly increasing a therapeutic effect through the preparation method of the present invention and dendritic cells cultured ex vivo using same can be provided. La présente invention concerne un procédé d'augmentation de l'immunité antitumorale d'un agent thérapeutique dendrocytaire et, plus spécifiquement, un procédé de préparation de cellules dendritiques positives à la classe de différenciation 103 (CD103), des cellules dendritiques positives à CD103 préparées par le procédé de préparation, ainsi qu'une composition pharmaceutique et un kit les comprenant pour une immunothérapie anticancéreuse ; le procédé comprenant une étape de traitement de cellules progénitrices dendrocytaires avec l'interleukine-33 (IL-33) lorsque les cellules progénitrices dendrocytaires sont cultivées dans un milieu contenant un ligand de tyrosine kinase 3 de type FMS (Flt3L) et ainsi différenciées en cellules dendritiques. Étant donné que les cellules dendritiques différenciées par le procédé de préparation de la présente invention présentent un potentiel élevé d'induction de lymphocytes T cytotoxiques spécifiques d'un antigène, par rapport aux cellules dendritiques témoins, et que l'immunité antitumorale est fortement induite par une sous-population des cellules dendritiques nouvellement différenciées, le procédé de préparation de la présente invention a l'avantage d'augmenter l'immunogénicité dans l'étape de différenciation par rapport à un procédé classique d'augmentation de l'immunogénicité après l'achèvement de la différenciation en cellules dendritiques. Par conséquent, il est prévu qu'une nouvelle thérapie par cellules immunitaires permettant d'augmenter fortement un effet thérapeutique par le biais du procédé de préparation de la présente invention et des cellules dendritiques cultivées ex vivo à l'aide de celui-ci puisse être fournie. 본 발명은 수지상세포 치료제의 항종양면역을 높이기 위한 방법에 관한 것으로서, 구체적으로 수지상세포 전구세포를 Flt3L (FMS-like tyrosine kinase 3 ligand)이 포함된 배지에서 배양하여 수지상세포로 분화 시킴에 있어서, 상기 수지상세포의 분화 단계에서 인터류킨-33 (Interleukin-33, IL-33)을 처리하는 단계를 포함하는 CD103 (cluster of differentiation 103) 양성 수지상세포의 제조방법, 상기 제조방법으로 제조된 CD103 양성 수지상세포, 이를 포함하는 면역항암치료용 약학적 조성물 및 키트 등에 관한 것이다. 본 발명의 제조방법에 의해 분화된 수지상세포는 대조군 수지상세포와 비교하여 항원 특이적 세포독성 T 세포 유도능이 높았으며, 새롭게 분화된 수지상세포 아군에 의해 항종양면역이 강력하게 유도되는 바, 수지상세포 분화 완료 후 면역원성을 높이는 기존의 방법과는 다르게 분화 단계에서 면역원성을 높일 수 있는 효과가 있다. 따라서 본 발명의 제조방법 및 이를 이용한 체외 배양 수지상세포를 통해 치료 효과를 비약적으로 상승시킬 수 있는 새로운 면역세포 치료법을 제공할 수 있을 것으로 기대된다.</description><language>eng ; fre ; kor</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220527&DB=EPODOC&CC=WO&NR=2022108306A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220527&DB=EPODOC&CC=WO&NR=2022108306A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HONG, Jung-Hyub</creatorcontrib><creatorcontrib>KANG, Myeongho</creatorcontrib><creatorcontrib>JEONG, Yideul</creatorcontrib><creatorcontrib>BAE, Yong-Soo</creatorcontrib><title>METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY</title><description>The present invention relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a pharmaceutical composition and kit comprising same for cancer immunotherapy, the method comprising a step of treating dendrocyte progenitor cells with interleukin-33 (IL-33) when the dendrocyte progenitor cells are cultured in a medium containing FMS-like tyrosine kinase 3 ligand (Flt3L) and thus differentiated to dendritic cells. As the dendritic cells differentiated by the preparation method of the present invention exhibit a high potential of inducing antigen-specific cytotoxic T cells, compared to control dendritic cells, and antitumor immunity is strongly induced by a subpopulation of the newly differentiated dendritic cells, the preparation method of the present invention has the advantage of increasing immunogenicity in the differentiation step in contrast to a convention method of increasing immunogenicity after completion of differentiation to dendritic cells. Therefore, it is expected that novel immune cell therapy capable of greatly increasing a therapeutic effect through the preparation method of the present invention and dendritic cells cultured ex vivo using same can be provided. La présente invention concerne un procédé d'augmentation de l'immunité antitumorale d'un agent thérapeutique dendrocytaire et, plus spécifiquement, un procédé de préparation de cellules dendritiques positives à la classe de différenciation 103 (CD103), des cellules dendritiques positives à CD103 préparées par le procédé de préparation, ainsi qu'une composition pharmaceutique et un kit les comprenant pour une immunothérapie anticancéreuse ; le procédé comprenant une étape de traitement de cellules progénitrices dendrocytaires avec l'interleukine-33 (IL-33) lorsque les cellules progénitrices dendrocytaires sont cultivées dans un milieu contenant un ligand de tyrosine kinase 3 de type FMS (Flt3L) et ainsi différenciées en cellules dendritiques. Étant donné que les cellules dendritiques différenciées par le procédé de préparation de la présente invention présentent un potentiel élevé d'induction de lymphocytes T cytotoxiques spécifiques d'un antigène, par rapport aux cellules dendritiques témoins, et que l'immunité antitumorale est fortement induite par une sous-population des cellules dendritiques nouvellement différenciées, le procédé de préparation de la présente invention a l'avantage d'augmenter l'immunogénicité dans l'étape de différenciation par rapport à un procédé classique d'augmentation de l'immunogénicité après l'achèvement de la différenciation en cellules dendritiques. Par conséquent, il est prévu qu'une nouvelle thérapie par cellules immunitaires permettant d'augmenter fortement un effet thérapeutique par le biais du procédé de préparation de la présente invention et des cellules dendritiques cultivées ex vivo à l'aide de celui-ci puisse être fournie. 본 발명은 수지상세포 치료제의 항종양면역을 높이기 위한 방법에 관한 것으로서, 구체적으로 수지상세포 전구세포를 Flt3L (FMS-like tyrosine kinase 3 ligand)이 포함된 배지에서 배양하여 수지상세포로 분화 시킴에 있어서, 상기 수지상세포의 분화 단계에서 인터류킨-33 (Interleukin-33, IL-33)을 처리하는 단계를 포함하는 CD103 (cluster of differentiation 103) 양성 수지상세포의 제조방법, 상기 제조방법으로 제조된 CD103 양성 수지상세포, 이를 포함하는 면역항암치료용 약학적 조성물 및 키트 등에 관한 것이다. 본 발명의 제조방법에 의해 분화된 수지상세포는 대조군 수지상세포와 비교하여 항원 특이적 세포독성 T 세포 유도능이 높았으며, 새롭게 분화된 수지상세포 아군에 의해 항종양면역이 강력하게 유도되는 바, 수지상세포 분화 완료 후 면역원성을 높이는 기존의 방법과는 다르게 분화 단계에서 면역원성을 높일 수 있는 효과가 있다. 따라서 본 발명의 제조방법 및 이를 이용한 체외 배양 수지상세포를 통해 치료 효과를 비약적으로 상승시킬 수 있는 새로운 면역세포 치료법을 제공할 수 있을 것으로 기대된다.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjr9KxEAQxtNYyOk7DFhKIMmC2I67k-xidnaZTDhSHcexVqIH5wv6ZiZylZXV9xXfn99t9R1JfXLQJ4EslFECDxBinDkNxMEGXWpij2zJgXVtYx6ht4Os4oidBA0WLI0jvCygQqiRWGEf1ENgJRlpfg1cGwPIDrJHiWhpXms4gk0xp2ndSPzrJUzb_4SR_s5vhHbDkCueehLMy11183Z8v5T7q-6qh57U-rqcPw_lcj6eykf5OuxT13Rd2zyb5glb87_UD71oTnY</recordid><startdate>20220527</startdate><enddate>20220527</enddate><creator>HONG, Jung-Hyub</creator><creator>KANG, Myeongho</creator><creator>JEONG, Yideul</creator><creator>BAE, Yong-Soo</creator><scope>EVB</scope></search><sort><creationdate>20220527</creationdate><title>METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY</title><author>HONG, Jung-Hyub ; KANG, Myeongho ; JEONG, Yideul ; BAE, Yong-Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022108306A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; kor</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>HONG, Jung-Hyub</creatorcontrib><creatorcontrib>KANG, Myeongho</creatorcontrib><creatorcontrib>JEONG, Yideul</creatorcontrib><creatorcontrib>BAE, Yong-Soo</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HONG, Jung-Hyub</au><au>KANG, Myeongho</au><au>JEONG, Yideul</au><au>BAE, Yong-Soo</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY</title><date>2022-05-27</date><risdate>2022</risdate><abstract>The present invention relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a pharmaceutical composition and kit comprising same for cancer immunotherapy, the method comprising a step of treating dendrocyte progenitor cells with interleukin-33 (IL-33) when the dendrocyte progenitor cells are cultured in a medium containing FMS-like tyrosine kinase 3 ligand (Flt3L) and thus differentiated to dendritic cells. As the dendritic cells differentiated by the preparation method of the present invention exhibit a high potential of inducing antigen-specific cytotoxic T cells, compared to control dendritic cells, and antitumor immunity is strongly induced by a subpopulation of the newly differentiated dendritic cells, the preparation method of the present invention has the advantage of increasing immunogenicity in the differentiation step in contrast to a convention method of increasing immunogenicity after completion of differentiation to dendritic cells. Therefore, it is expected that novel immune cell therapy capable of greatly increasing a therapeutic effect through the preparation method of the present invention and dendritic cells cultured ex vivo using same can be provided. La présente invention concerne un procédé d'augmentation de l'immunité antitumorale d'un agent thérapeutique dendrocytaire et, plus spécifiquement, un procédé de préparation de cellules dendritiques positives à la classe de différenciation 103 (CD103), des cellules dendritiques positives à CD103 préparées par le procédé de préparation, ainsi qu'une composition pharmaceutique et un kit les comprenant pour une immunothérapie anticancéreuse ; le procédé comprenant une étape de traitement de cellules progénitrices dendrocytaires avec l'interleukine-33 (IL-33) lorsque les cellules progénitrices dendrocytaires sont cultivées dans un milieu contenant un ligand de tyrosine kinase 3 de type FMS (Flt3L) et ainsi différenciées en cellules dendritiques. Étant donné que les cellules dendritiques différenciées par le procédé de préparation de la présente invention présentent un potentiel élevé d'induction de lymphocytes T cytotoxiques spécifiques d'un antigène, par rapport aux cellules dendritiques témoins, et que l'immunité antitumorale est fortement induite par une sous-population des cellules dendritiques nouvellement différenciées, le procédé de préparation de la présente invention a l'avantage d'augmenter l'immunogénicité dans l'étape de différenciation par rapport à un procédé classique d'augmentation de l'immunogénicité après l'achèvement de la différenciation en cellules dendritiques. Par conséquent, il est prévu qu'une nouvelle thérapie par cellules immunitaires permettant d'augmenter fortement un effet thérapeutique par le biais du procédé de préparation de la présente invention et des cellules dendritiques cultivées ex vivo à l'aide de celui-ci puisse être fournie. 본 발명은 수지상세포 치료제의 항종양면역을 높이기 위한 방법에 관한 것으로서, 구체적으로 수지상세포 전구세포를 Flt3L (FMS-like tyrosine kinase 3 ligand)이 포함된 배지에서 배양하여 수지상세포로 분화 시킴에 있어서, 상기 수지상세포의 분화 단계에서 인터류킨-33 (Interleukin-33, IL-33)을 처리하는 단계를 포함하는 CD103 (cluster of differentiation 103) 양성 수지상세포의 제조방법, 상기 제조방법으로 제조된 CD103 양성 수지상세포, 이를 포함하는 면역항암치료용 약학적 조성물 및 키트 등에 관한 것이다. 본 발명의 제조방법에 의해 분화된 수지상세포는 대조군 수지상세포와 비교하여 항원 특이적 세포독성 T 세포 유도능이 높았으며, 새롭게 분화된 수지상세포 아군에 의해 항종양면역이 강력하게 유도되는 바, 수지상세포 분화 완료 후 면역원성을 높이는 기존의 방법과는 다르게 분화 단계에서 면역원성을 높일 수 있는 효과가 있다. 따라서 본 발명의 제조방법 및 이를 이용한 체외 배양 수지상세포를 통해 치료 효과를 비약적으로 상승시킬 수 있는 새로운 면역세포 치료법을 제공할 수 있을 것으로 기대된다.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre ; kor
recordid	cdi_epo_espacenet_WO2022108306A1
source	esp@cenet
subjects	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
title	METHOD FOR PREPARING IMMUNOGENICITY-ENHANCED CD103+ FCGR3+ DENDRITIC CELL BY TREATMENT WITH INTERLEUKIN-33 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DENDRITIC CELL FOR CANCER IMMUNOTHERAPY
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T15%3A14%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HONG,%20Jung-Hyub&rft.date=2022-05-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022108306A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true